. 2023 Jul 22;7(6):856–862. doi: 10.1002/ags3.12717

TABLE 1.

Trials investigating the efficacy of preoperative neoadjuvant chemotherapy (including ongoing and international trials).

Trial/authors	Phase	Patients	Arms	No. of patients	5Y‐PFS	5Y‐OS	Hazard ratio for OS (95% CI)
JCOG1509 ¹⁰	III	cStrage III	S: surgery + S‐1/DS	235 ^a	Ongoing
JCOG1509 ¹⁰	III	cStrage III	E: SOX + surgery + S‐1/DS	235 ^a	Ongoing
PRODIGY ¹¹	III	T2‐3N+ or T4Nany	S: surgery + S‐1	264	60.2 ^b
PRODIGY ¹¹	III	T2‐3N+ or T4Nany	E: DOS + surgery + S‐1	266	66.3 ^b		0.70 (0.52–0.95) ^c
FLOT ¹²		≥T2 and/or N+	S: ECF(ECX) + surgery + ECF(ECX)	360		36%
FLOT ¹²		≥T2 and/or N+	E: FLOT + surgery + FLOT	356		45%	0.77 (0.63–0.94)
NAC for GC with extended LN metastasis
JCOG0405 ⁷	II	Extended LN metastasis	SP + surgery	51		53%	–
JCOG1002 ⁸	II	Extended LN metastasis	DCS + surgery + S‐1	52		55%	–
JCOG1704 ¹³	II	Extended LN metastasis	DOS + surgery + S‐1	46	Ongoing
NAC for schirrous type GC
JCOG0501 ⁹	III	Type 4/large type 3	S: surgery + S‐1	149	48% ^b	62% ^d
JCOG0501 ⁹	III	Type 4/large type 3	E: SP + surgery + S‐1	151	48% ^b	61% ^d	0.92 (0.68–1.23)

Abbreviations: DCS, docetaxel + cisplatin + S‐1; DOS, docetaxel + oxaliplatin + S‐1; DS, docetaxel + S‐1; E, experimentary arm; ECF, epirubicin, cisplatin, fluorouracil; ECX, epirubicin, cisplatin, capecitabine; FLOT, 5‐fluorouracil + leucovorin + oxaliplatin + docetaxel; LN, lymph node; S, standard arm; SOX, S‐1 + oxaliplatin; SP, S‐1 + cisplatin.

^{^a}

Planed number of patients recruited for the study.

^{^b}

3Y‐PFS.

^{^c}

Hazard ratio for PFS.

^{^d}

3Y‐OS.